Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 5/20 | 0.55 |
| ▸ | EPHA2 | P29317 | 13/20 | 0.51 |
| ▸ | KDR | P35968 | 7/20 | 0.51 |
| ▸ | RET | P07949 | 1/20 | 0.48 |
| ▸ | KIF5B | P33176 | 1/20 | 0.48 |
| ▸ | EPHB4 | P54760 | 6/20 | 0.47 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.47 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.46 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5648641 | 0.88 | KDR (0.53) | EGFREPHA2KDRRETKIF5B | |
| SCHEMBL5649287 | 0.87 | EGFR (0.60) | EGFRKDRRETERBB2RIPK2 | |
| SCHEMBL5651823 | 0.84 | EPHA2 (0.66) | EGFREPHA2KDRRETKIF5B | |
| SCHEMBL5648557 | 0.83 | KDR (0.62) | EGFRKDRRIPK2EPHB2 | |
| SCHEMBL5647905 | 0.83 | KDR (0.62) | EGFRKDRRIPK2EPHB2 | |
| SCHEMBL5650271 | 0.81 | EPHA2 (0.71) | EGFREPHA2KDREPHB4ERBB2 | |
| SCHEMBL5652282 | 0.81 | EGFR (0.57) | EGFRKDR | |
| SCHEMBL5652851 | 0.80 | KDR (0.68) | EGFREPHA2KDRRETKIF5B | |
| SCHEMBL5650307 | 0.80 | KDR (0.63) | EGFRKDR | |
| SCHEMBL5651349 | 0.79 | KDR (0.49) | EGFRKDRERBB2RIPK2EPHB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070299092-A1 | Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors | WYETH (US) | 2007-12-27 | — | — | US | disclosed |
| WO-2005115145-A2 | QUINONE SUBSTITUTED QUINAZOLINE AND QUINOLINE KINASE INHIBITORS | WYETH (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299092-A1 | Quinone Substituted Quinazoline and Quinoline Kinase Inhibitors | KDR, FLT1, FLT4 | EGFR 439/4885EPHA2 814/4885KDR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.